Status:
COMPLETED
Cognitive Benefits of Aerobic Exercise Across the Age Span
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Cognitive Function
Eligibility:
All Genders
20-68 years
Phase:
NA
Brief Summary
The purpose of this study is to test the hypothesis that aerobic exercise leads improved cognitive function accompanied by increases in gray matter density and changes in functional magnetic resonance...
Detailed Description
While animal and human studies indicate cognitive benefits from aerobic exercise across the lifespan, the great majority of controlled exercise studies in humans have been restricted to elderly indivi...
Eligibility Criteria
Inclusion
- Age 20-68
- English-speaking
- strongly right-handed
- BMI \< 35
- Pre-menopausal (women only): no oral contraceptive use Post-menopausal: no estrogen replacement therapy
- sedentary: VO2 max \< 41 and 31.6 ml/kg/min for men age 20-40 and 50-68 and \< 35.2 and 26.6 ml/kg/min for women age 20-40 and 50-68 respectively
- participants over age 60 must have ECG within past 3 months
Exclusion
- MRI contraindications (e.g., metallic implants, pacemaker, weight \> 350 lbs, waist \> 55")
- Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective lenses
- Objective cognitive impairment
- Ischemic changes, abnormal blood pressure responses, or any significant ectopy during aerobic capacity testing
- Cardiovascular disease
- Uncontrolled high blood pressure (systolic blood pressure ≥ 140 mmHg; or diastolic blood pressure ≥ 90 mmHg on two measures)
- Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma
- Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II).
- HIV infection
- Pregnant or lactating (participation allowed 3 months after ceasing lactation
- Medications that target CNS (central nervous system, e.g., neuroleptics, anticonvulsants, antidepressants, benzodiazepines) within the last month
- Women: any selective estrogen receptor modulator or aromatase inhibitor Men: androgen ablation/deprivation hormonal therapies
- Any history of psychosis or electroconvulsive therapy
- Psychotic disorder (lifetime)
- Current or recent (within past 12 months) alcohol or substance abuse or dependence. Recent use (past month) of recreational drugs.
- Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury, mental retardation
- Imaged cortical stroke or large subcortical lacunae or infarct or space-occupying lesion (≥ 2 cubic cm). Other findings, e.g., periventricular caps or small white matter hyperintensities, do not result in exclusion
- Diagnosed learning disability, dyslexia
- Current or recent (Past 5 years) Major Depressive Disorder, Bipolar Disorder, or Anxiety Disorder
- Dementia Rating Scale \< 135
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2016
Estimated Enrollment :
305 Patients enrolled
Trial Details
Trial ID
NCT01179958
Start Date
August 1 2010
End Date
June 29 2016
Last Update
August 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Richard Sloan
New York, New York, United States, 10013